Company Profile

ACADIA Pharmaceuticals Inc
Profile last edited on: 1/22/2019      CAGE: 5LB84      UEI: D79ND8GZR3E6

Business Identifier: Small molecule drugs: neurological and psychiatric disorders
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3611 Valley Centre Drive Suite 300
San Diego, CA 92121
   (858) 558-2871
Location: Multiple
Congr. District: 52
County: San Diego

Public Profile

ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA Pharmaceuticals has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. All of ACADIA's product candidates emanate from discoveries made using the firm's proprietary drug discovery platform. ACADIA also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc. as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 2 NIH $1,466,942
Project Title: Development of Estrogen Receptor B Selective Receptor Agonists to Treat Neuropath
2000 1 NIH $119,463
Project Title: Constitutively Active Receptors in Psychiatric Disease

Key People / Management

  Mark R Brann -- President

  Stephen R Davis -- President and CEO

  Thomas H Aasen -- Executive Vice President, Chief Financial Officer, and Chief Business Officer

  Glenn Baity -- Executive Vice President, General Counsel and Secretary

  Leonard Bormann -- Former CEO

  Ethan Samuel Burstein

  Daryl DeKarske -- Senior Vice President

  Uli Hacksell -- Former CEO

  Fred W Manak -- Senior Vice President

  Roger G Mills -- Executive Vice President, Development and Chief Medical Officer

  Bob Mischler -- Senior Vice President, Strategy and Business and Development

  Terrence Moore -- Executive Vice President and Chief Commercial Officer

  James A Nash -- Senior Vice President, Technology Development and Operations

  Randall Owen -- Senior Vice President, Clinical Development and CMO

  Serge Stankovic -- Executive Vice President ; Head of Research and Development

  David M Weiner

  Michael J Yang -- Executive Vice President ; Chief Commerical Officer

  Todd S Young -- Executive Vice President ; CFO